For example, patients with NSCLC are routinely tested for the presence of fusions in ALK, RET, ROS1, and MET exon 14 skipping in a single RNA-based assay that can often easily be expanded with the NTRK1–3 fusions. This evidence concerns the gene MET and non-small cell lung carcinoma.